Zobrazeno 1 - 4
of 4
pro vyhledávání: '"S. Z. Safina"'
Autor:
E. V. Borodavina, P. A. Isaev, A. Yu. Shurinov, P. O. Rumyantsev, V. V. Krylov, K. M. Petrosyan, A. D. Kaprin, S. A. Ivanov, S. O. Podvyaznikov, I. S. Romanov, A. M. Mudunov, K. Yu. Slashchuk, R. S. Zhikhorev, M. V. Volkonsky, R. M. Chagova, I. R. Suslova, A. I. Khryapa, A. Kh. Lepshokova, N. L. Fadeeva, A. R. Safarova, L. P. Kaleykina, E. V. Lymar, E. M. Chernyakova, O. A. Snezhko, A. E. Zinkovskaya, F. F. Mufazalov, E. S. Kuzmina, Yu. V. Druzhinina, Sh. I. Musin, M. R. Mukhitova, A. I. Khasanova, S. Z. Safina, S. L. Kirienko
Publikováno v:
Опухоли головы и шеи, Vol 10, Iss 1, Pp 65-72 (2020)
Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatment outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for these p
Externí odkaz:
https://doaj.org/article/90b3f88358a64191b3df59c14333279c
Autor:
A. I. Khryapa, E. M. Chernyakova, F. F. Mufazalov, E. V. Lymar, S. A. Ivanov, K. Yu. Slashchuk, N. L. Fadeeva, R. M. Chagova, V. V. Krylov, A. R. Safarova, A. M. Mudunov, S. Z. Safina, M. R. Mukhitova, A. I. Khasanova, S. O. Podvyaznikov, K. M. Petrosyan, I. R. Suslova, R. S. Zhikhorev, A. Kh. Lepshokova, P. A. Isaev, S. L. Kirienko, Yu. V. Druzhinina, I. S. Romanov, E. S. Kuzmina, Andrey Kaprin, Sh. I. Musin, O. A. Snezhko, A. Yu. Shurinov, L. P. Kaleykina, A. E. Zinkovskaya, Pavel O. Rumyantsev, M. V. Volkonsky, E. V. Borodavina
Publikováno v:
Opuholi Golovy i Šei, Vol 10, Iss 1, Pp 65-72 (2020)
Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatment outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for these p
Autor:
S. Z. Safina, S. A. Varlamov, A. V. Snegovoy, I. S. Varlamov, L. I. Gurina, L. V. Manzuk, I. V. Tsimafeyeu
Publikováno v:
Onkourologiâ, Vol 13, Iss 4, Pp 40-44 (2018)
Background. In a CRAD001LRU02T study of everolimus for metastatic renal cell carcinoma patients previously treated with bevacizumab ± interferon, median overall survival (OS) was 17.4 months (95 % confidence interval 13.5–21.3 month).Objective of
Autor:
E V Artamonova, E I Kovalenko, A V Snegovoy, A A Aksarin, T A Anciferova, A V Belonogov, E V Bilan, S N Bilenko, I M Varvus, E A Gorkovenko, R F Enikeev, A M Ermolaeva, L V Kramskaya, I B Kononenko, A P Pechenyy, S Z Safina, T V Chupriyanova, G G Chuhua, A I Shemyakina, E V Shikina
Publikováno v:
Современная онкология, Vol 20, Iss 3, Pp 19-25 (2018)
Background and aims. There is no data on olaparib efficacy and safety in Russian routine clinical practice. Methods. We analysed the 30 consecutive patients who received maintenance olaparib treatment for platinum-sensitive relapse (PSR) of ovarian o
Externí odkaz:
https://doaj.org/article/dd31107e3e054b2f8a0745e52e2e870d